Citadel Advisors
CTXR icon

Citadel Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Citadel Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.5K Buy
+124,910
New +$84.6K ﹤0.01% 12876
2025
Q1 		– Sell
-1
Closed -$2 – 14624
2024
Q4 		$4 Buy
+1
New +$7 ﹤0.01% 14402
2024
Q3 		– Sell
-7,425
Closed -$125K – 14360
2024
Q2 		$108K Buy
+7,425
New +$133K ﹤0.01% 10808
2023
Q4 		– Sell
-194
Closed -$3.68K – 14385
2023
Q3 		$3.32K Buy
194
+163
+526% +$3.87K ﹤0.01% 13598
2023
Q2 		$944 Sell
31
-3,461
-99% -$114K ﹤0.01% 14015
2023
Q1 		$102K Sell
3,492
-12,195
-78% -$352K ﹤0.01% 11233
2022
Q4 		$310K Buy
15,687
+11,432
+269% +$312K ﹤0.01% 9244
2022
Q3 		$129K Sell
4,255
-5,180
-55% -$142K ﹤0.01% 10858
2022
Q2 		$217K Buy
9,435
+4,954
+111% +$136K ﹤0.01% 10526
2022
Q1 		$200K Sell
4,481
-1,044
-19% -$41.2K ﹤0.01% 11540
2021
Q4 		$213K Buy
5,525
+910
+20% +$41.3K ﹤0.01% 11721
2021
Q3 		$234K Sell
4,615
-3,753
-45% -$188K ﹤0.01% 11620
2021
Q2 		$728K Buy
8,368
+7,248
+647% +$436K ﹤0.01% 9167
2021
Q1 		$50K Buy
1,120
+364
+48% +$14.5K ﹤0.01% 12897
2020
Q4 		$19K Buy
+756
New +$19.7K ﹤0.01% 10785
2020
Q3 		– Sell
-697
Closed -$20K – 10150
2020
Q2 		$20K Buy
697
+271
+64% +$5.93K ﹤0.01% 9549
2020
Q1 		$6K Buy
+426
New +$9K ﹤0.01% 9471
2019
Q2 		– Sell
-1,063
Closed -$38K – 9254
2019
Q1 		$38K Buy
+1,063
New +$31.3K ﹤0.01% 8918

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
BW
BostonPremier Wealth Hanover, Massachusetts $235M AUM 31.01% 1-Year Est. Return

Citadel Advisors's CTXR Position: Q2 2026 in Review

Citadel Advisors opened a new position in Citius Pharmaceuticals (CTXR) in Q2 2026: 124,910 shares worth $75.5K. The stake represents ﹤0.01% of the portfolio and ranks #12876 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CTXR as recently as Q4 2024.

Citadel Advisors first reported a position in CTXR in Q1 2019 and has held it in 18 quarters since. The position peaked at $728K in Q2 2021. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • Citadel Advisors held 124,910 shares of Citius Pharmaceuticals worth $75.5K as of Q2 2026.
  • Citius Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
  • Citius Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12876 holding.
  • Citadel Advisors first reported a position in Citius Pharmaceuticals in Q1 2019 and has held it in 18 quarters since.
  • Citadel Advisors's Citius Pharmaceuticals position peaked at $728K in Q2 2021.
  • 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.